July 16 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA PLC - UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS
ASTRAZENECA: RESULTS DID NOT ACHIEVE STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT IN OVERALL PATIENT POPULATION
ASTRAZENECA PLC - EVALUATION OF ANSELAMIMAB RESULTS ONGOING
ASTRAZENECA: ANSELAMIMAB SHOWED CLINICALLY MEANINGFUL IMPROVEMENT IN TIME TO ACM, FREQUENCY OF CVH IN PRESPECIFIED SUBGROUP OF PATIENTS VERSUS PLACEBO